Madopar (パーキンソン病)：医薬品市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 20
4.1 Overview 20
4.1.1 Diagnosis – The UK Brain Bank Criteria 20
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.2 Treatment Synopsis 24
4.2.1 Dopaminergic Therapy Classes 24
4.2.2 Treatment of Parkinson’s Disease by Stage 26
4.2.3 Other Treatment Options 29
4.3 Parkinson’s Disease Assessment Scales 29
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 30
4.3.2 Hoehn and Yahr Clinical Staging 32
4.3.3 Other Clinical Assessments 33
5 Competitive Assessment 34
5.1 Overview 34
5.2 Strategic Competitor Assessment 36
5.3 Product Profiles – Levodopa Combination Therapy 38
6 Madopar (levodopa/benserazide) 39
6.1 Overview 39
6.2 Efficacy 40
6.3 Safety 41
6.4 SWOT Analysis 42
6.5 Forecast 42
7 Appendix 45
7.1 Bibliography 45
7.2 Abbreviations 49
7.3 Methodology 52
7.4 Forecasting Methodology 52
7.4.1 Diagnosed Parkinson’s Disease Patients 52
7.4.2 Percent Drug-Treated Patients 53
7.4.3 General Pricing Assumptions 53
7.4.4 Compliance Assumptions 54
7.4.5 Individual Drug Assumptions 55
7.4.6 Generic Erosion 56
7.5 Physicians and Specialists Included in this Study 57
7.6 About the Authors 59
7.6.1 Author 59
7.6.2 Global Head of Healthcare 60
7.7 About GlobalData 61
7.8 Disclaimer 61